MedTrace Logo

Dexmedetomidine on Microcirculation in Septic Shock

NCT02270281 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2018-12-12

No results posted yet for this study

Summary

Dexmedetomidine was found might be beneficial to sepsis. Dexmedetomidine were found to improve microcirculation in sepsis animal studies and non-sepsis patients. However, the effect of dexmedetomidine on microcirculation in septic shock patients is unknown.

Conditions

  • Septic Shock

Interventions

DRUG

Dexmedetomidine 0.7 Mcg/kg/h

CIF 0.7mcg/kg/h

Sponsors & Collaborators

  • Southeast University, China

    lead OTHER

Principal Investigators

  • fengmei Guo, MD,PhD · Southeast University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-12-31
Completion
2017-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02270281 on ClinicalTrials.gov